Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ITGAM | P11215 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525511 | 0.91 | ITGB3 (0.41) | LMNASMN1; SMN2ITGB3ITGA2BITGB2 | |
| SCHEMBL7534058 | 0.89 | ITGB3 (0.43) | ITGB3ITGA2BITGB2ITGAMMIF | |
| SCHEMBL7528845 | 0.84 | ITGB3 (0.43) | ITGB3ITGA2BITGB2ITGAMMIF | |
| SCHEMBL7532410 | 0.84 | ITGB3 (0.42) | ITGB3ITGA2BITGB2ITGAMMIF | |
| SCHEMBL7529746 | 0.83 | ITGB3 (0.38) | LMNASMN1; SMN2ITGB3ITGA2BITGB2 | |
| SCHEMBL7531075 | 0.83 | BLM (0.39) | LMNASMN1; SMN2ITGB3ITGA2BITGB2 | |
| SCHEMBL7529236 | 0.82 | ITGB3 (0.40) | ITGB3ITGA2BITGB2ITGAMMIF | |
| SCHEMBL7536611 | 0.81 | ITGB3 (0.58) | ITGB3ITGA2BITGB2ITGAM | |
| SCHEMBL7526593 | 0.81 | LMNA (0.41) | LMNASMN1; SMN2MIF | |
| SCHEMBL7533130 | 0.80 | ITGB3 (0.48) | ITGB3ITGA2BITGB2ITGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6476226-B2 | PLATELET GLYCOPROTEIN IIB/IIIA FIBRINOGEN; ANTICOAGULANTS; THROMBOLYTIC AGENTS; THROMBOEMBOLIC DISORDERS; ANTIINFLAMMATORY AGENTS; BONE DISORDERS; ANTITUMOR, -METASTASIS, -ARTHRITIC AGENTS; ASTHMA; PSORIASIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-18 | — | — | US | disclosed |
| US-6303609-B1 | USED FOR THE INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | F13B, F11, FGB | LMNA 3189/4885SMN1; SMN2 4508/4885ITGB3 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.